Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch Negativity
Gabrielle Allohverdi, Milad Soltanzadeh, André Schmidt, Colleen E. Charlton, Daniel J. Hauke, Povilas Karvelis, Franz X. Vollenweider, Andreea O. Diaconescu
bioRxiv (Cold Spring Harbor Laboratory) November 7, 2025 preprint DOI: 10.1101/2025.11.06.687023 via OpenAlex
Summary
AI-generated from the abstractKetamine and psilocybin, two hallucinogenic compounds being explored as treatments for major depressive disorder, affect sensory learning in the brain differently. By combining computational modeling with electroencephalography (EEG) data from a prior experiment, researchers analyzed how these drugs alter the brain's processing of unexpected sounds during an auditory task. Ketamine produced a larger reduction in the influence of sensory precision between 207 and 316 milliseconds after a sound, peaking at 277 milliseconds in frontal central brain regions, while psilocybin showed no significant effect in that measure. Both drugs reduced the expression of belief precision between 160 and 184 milliseconds, peaking at 172 milliseconds.
Study at a glance
| Characteristics | Placebo-controlled within-subject crossover design |
|---|---|
| Population | Healthy subjects |
| Interventions | S-ketamine psilocybin |
| Topics | Ketamine Psilocybin |
| Keywords | Sensory system Electroencephalography Psychotomimetic |
| Key finding | Ketamine and psilocybin have distinct effects on hierarchical sensory learning in the auditory mismatch negativity paradigm, with ketamine reducing sensory precision more than placebo and psilocybin showing no significant effect on that measure. |
Abstract
Abstract Ketamine and psilocybin show potential as therapies for various mental illnesses, including major depressive disorder. However, further investigation into their neural mechanisms is required to understand their effects on the brain. By combining computational modelling with electroencephalography (EEG), we examine the effects of ketamine and psilocybin on hierarchical sensory pwPE learning in the context of the auditory mismatch negativity, an event-related potential consistently shown to be reduced under psychotomimetic interventions. We employed a Bayesian framework and re-analyzed a previously acquired EEG dataset (Schmidt et al., 2012) by modelling single-trial EEG data using the Hierarchical Gaussian Filter. Using a placebo-controlled within-subject crossover design, healthy subjects were administered either S-ketamine or psilocybin during an auditory roving paradigm of pure sinusoidal tones. Our findings elucidate distinct neural impacts of ketamine and psilocybin on sensory learning: ketamine led to a larger reduction in the effect of sensory precision compared to placebo from 207 to 316 ms peaking at 277 ms in the frontal central channels, while psilocybin showed no significant effect. Both drugs reduced the expression of belief precision between 160 to 184 ms, peaking at 172 ms. For higher-level volatility pwPEs, ketamine reduced the expression at 312 ms while psilocybin had a null effect. For perception of elementary imagery, ketamine had a greater effect than psilocybin on sensory and volatility precision, while psilocybin had a greater effect on volatility pwPEs. Our findings suggest hallucinogens have distinct effects on sensory learning that could inform tailored therapies for major depression.